The trial is a multi-centric, randomised, open label clinical study to evaluate the efficacy, safety and tolerability of Niclosamide for treating hospitalised COVID-19 patients.
COVID second wave affects trial of new drugs
Updated:
Updated:
IICT has lined up at least three potential repurposed drugs for clinical trials
Share Article
IICT has lined up at least three potential repurposed drugs for clinical trials
The surging second wave of COVID-19 pandemic has been putting tremendous strain on the healthcare facilities in both the public and private sector with scores of patients lining up for admission. This has also had an effect on the ongoing clinical trials for various drugs and vaccine candidates even as hospitals and staff remain busy with patient care.
CSIR-Indian Institute of Chemical Technology (IICT) has lined up at least three potential repurposed drugs Niclosamide, Colchicine and Chlorpromazine in association with other CSIR labs for clinical trials. “While this is the time to initiate clinical trials with many patients being admitted in hospitals, we are conscious that it will also put pressure on doctors partnering for clinical tri
Bharat Biotech s BSL-3 aims to produce 700 million doses of Covaxin per annum
IANSApr 29, 2021, 12:50 IST
TOI
Biotechnology major Bharat Biotechs BSL-3 (Biosafety Level-3) facilities will play a pivotal role in empowering the company s plans to ramp-up production of India s first indigenously developed Covid-19 vaccine.
Accordingly, the biotechnology major plans to produce 700 million doses of
Covaxin per annum. The vaccine is regarded as one of the safest in the world and highly efficient against the UK, SA, Brazilian and the new Indian double mutant strain of Covid-19 virus.
Advertisement
In a conversation with IANS, Krishna Ella, Chairman and Managing Director of
Bharat Biotech International said the capacity expansion process has been initiated across multiple facilities since early 2021.
Covid Slayer: Bharat Biotech s BSL-3 facilities key to achieving 700M doses production
By
Rohit Vaid ( IANS) |
Published on
Thu, Apr 29 2021 12:21 IST |
26 Views
Covid Slayer: Bharat Biotech s BSL-3 facilities key to achieving 700M doses production.. Image Source: IANS News
New Delhi, April 29 : Biotechnology major Bharat Biotechs BSL-3 (Biosafety Level-3) facilities will play a pivotal role in empowering the companys plans to ramp-up production of Indias first indigenously developed Covid-19 vaccine.
Accordingly, the biotechnology major plans to produce 700 million doses of Covaxin per annum.
The vaccine is regarded as one of the safest in the world and highly efficient against the UK, SA, Brazilian and the new Indian double mutant strain of Covid-19 virus.
‘With vaccines, we can even eliminate this pandemic’
Updated:
Updated:
April 28, 2021 23:53 IST
NIN director advocates diet of fruits, vegetables and pulses plus nuts along with lowering of cereals intake
Share Article
AAA
NIN director advocates diet of fruits, vegetables and pulses plus nuts along with lowering of cereals intake
ICMR-National Institute of Nutrition (NIN) director R. Hemalatha has said that the latest data across the world has shown that vaccines taken in double dose spread over a period of few weeks is safe and efficacious in preventing severe infection even if one contracts COVID-19.
“We can even eliminate this pandemic as vaccines have proven to be successful earlier, whether it was for small pox or polio. Two doses are required for a person as the first dose stimulates our immune system to generate neutralising antibodies from seven days up to two/three or four weeks. The second dose makes it (immune response) stronger as the first one may not b